ArticleBMC psychiatry2025
Blue light treatment of psychiatric disorders: relationships with systemic inflammation, lipid metabolism, and clinical symptoms.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsychiatric disorders impose a substantial burden on individuals and society, and current treatment exhibit limited efficacy. Emerging evidence indicates that blue light exposure can influence mood and psychiatric conditions, yet its underlying mechanisms are not fully understood. Since that systemic inflammation is regarded as an important factor in mental health, this study explores the potential relationships between blue light therapy, immune-related pathways, and psychiatric symptoms.
methodIn this single-center retrospective study, medical records from 270 hospitalized psychiatric patients were analyzed. Patients received either routine treatment alone or in combination with blue light therapy, and were further stratified by season, treatment duration, and primary diagnosis.
resultsBlue light therapy was related to significant changes in key inflammation markers and psychiatric symptoms. Notably, we observed seasonal variations in the relationship between immune markers and specific psychiatric symptoms following blue light therapy.
conclusionBlue light therapy may offer a promising adjunctive approach for psychiatric disorders potentially through its associations with systemic inflammation and related symptoms. More studies are needed to explore its pathology and potential applications in clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.